Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Glanbia Nutritionals Inc. maintains 1 pending office action in the Biotechnology & Pharmaceuticals technology area. Prosecution is concentrated under 1 distinct examiner and 1 distinct art unit. CHI, AMANDA LYNN is the busiest examiner, managing 1 busiest examiner pending office action for the company. This single matter defines the company's current active engagement with the patent office.
The presence of 1 pending office action suggests a focused prosecution stage. Because the portfolio involves a single examiner and a single art unit, the current legal strategy is concentrated within a specific specialized division. Practitioners should prepare for a direct dialogue with the assigned official, as this individual holds responsibility for the company's only pending matter in this technology area. This structure simplifies the management of the company's intellectual property assets.
Navigating the Biotechnology & Pharmaceuticals sector with a single active case allows for a specific focus on the requirements of the assigned art unit. The outcome of this pending action will be determined by the standards of that group and the individual review of the examiner. This concentration minimizes the complexity found when multiple officials are involved in a portfolio.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHI, AMANDA LYNN | 1 | — | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18587819 | SHELF STABLE ORGANIC NUCLEOTIDE COMPOSITIONS AND METHODS OF MANUFACTURING THE SAME | CHI, AMANDA LYNN | 26d overdue |
| Art Unit | Apps |
|---|---|
| 1613 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18587819 | SHELF STABLE ORGANIC NUCLEOTIDE COMPOSITIONS AND METHODS OF MANUFACTURING THE SAME | CHI, AMANDA LYNN | 1613 | §103§112 | Final Rejection | 26d overdue | Pending | Feb 26, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial